The pharmacotherapy practices of clinical pharmacist in Department of Critical Care Medicine

CAO Wei; FANG Jie

doi:10.3969/j.issn.1006-0111.2017.04.021

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To discuss the knowledge and skills that clinical pharmacist should master to successfully perform the work in Department of Critical Care Medicine. Methods To illustrate the problem solving process with case studies in critical care setting. Results Clinical pharmacists communicate with the healthcare workers actively to provide professional pharmaceutical knowledge with evidence-based pharmacy in taking care of critical patients. Conclusion Clinical pharmacists in Department of Critical Care Medicine should possess extensive clinical and pharmaceutical knowledge, actively apply evidence-based pharmacy, and pay attention to every details in drug administration and therapy.

The pharmacotherapy practices of clinical pharmacist in Department of Critical Care Medicine

1. Department of Pharmacy, First Hospital Affiliated to Xiamen University, Xiamen 361003, China

2. Department of Pharmacy, Rui Jin Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China

Received Date: 2016-11-24

Rev Recd Date: 2017-03-06

Key words:

Abstract: Objective To discuss the knowledge and skills that clinical pharmacist should master to successfully perform the work in Department of Critical Care Medicine. Methods To illustrate the problem solving process with case studies in critical care setting. Results Clinical pharmacists communicate with the healthcare workers actively to provide professional pharmaceutical knowledge with evidence-based pharmacy in taking care of critical patients. Conclusion Clinical pharmacists in Department of Critical Care Medicine should possess extensive clinical and pharmaceutical knowledge, actively apply evidence-based pharmacy, and pay attention to every details in drug administration and therapy.

HTML

Reference (18)

[1]	刘青,王泰龄. 慢加急性肝衰竭(ACLF)共识纪要:亚太肝病学会推荐(APASL)[J]. 临床肝胆病杂志[J],2010,26(1):13-18.
[2]	刘海华,王锦权. 脓毒症致急性肾损伤发病机制和临床防治的研究进展[J]. 感染、炎症、修复,2009,10(2):126-128.
[3]	Jay P Sanford. 热病——桑福德抗微生物治疗指南[M]. 范洪伟等译.44版. 北京:中国协和医科大学出版社,2015:211-213.
[4]	陈灏珠,林果为. 实用内科学[M].13版. 北京:人民卫生出版社,2012:2173-2174.
[5]	Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill:challenges and potential solutions[J]. Lancet Infect Dis, 2014,14(6):498-509.
[6]	Ulldemolins M, Soy D, Llaurado-Serra M, et al. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy:influence of residual diuresis on dose requirements[J]. Antimicrob Agents Chemother, 2015,59(9):5520-5528.
[7]	国家药典委员会. 中华人民共和国药典2015年版四部[S]. 北京:中国医药科技出版社,2015:118.
[8]	Rowland M, Tozer TN. 临床药代动力学与药效动力学 [M]. 陈东生等译.4版. 北京:人民卫生出版社,2012:112.
[9]	Williams MF, Dukes GE, Heizer W, et al. Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine[J]. Pharm Res,1992,9(9):1190-1194.
[10]	杨文琳,王美霞. 血液净化救治急性药物或毒物中毒[J]. 中国危重病急救医学,2005,17 (11):704-704.
[11]	尧国胜,李军,黄高,等. 急性重症中毒血液净化治疗的进展[J]. 右江民族医学院学报,2015,37(1):131-134.
[12]	Rhodes NJ, MacVane SH, Kuti JL, et al. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes[J]. Clin Infect Dis, 2014,59(6):905-907.
[13]	Luke DR, Wood ND, Tomaszewski KE, et al. Pharmacokinetics of sulfobutylether-b-cyclodextrin (SBECD) in subjects on hemodialysis[J]. Nephrol Dial Transplant,2012,27(3):1207-1212.
[14]	Hafner V, Czock D, BurhenneJ, et al.Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration[J]. Antimicrob Agents Chemother, 2010,54(6):2596-2602.
[15]	Kiser TH, Fish DN, Aquilante CL, et al.Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy[J]. Crit Care, 2015,18(3):32-40.
[16]	Turner RB, Martello JL, Malhotra A. Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole:A systematic review[J]. Int J Antimicrob Agents, 2015,46(4):362-366.
[17]	Atiq F, van den Bemt PM, Leebeek FW, et al. A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency[J]. Eur J Clin Pharmacol, 2015,71(8):921-929.
[18]	Park D, Southern W, Calvo M, et al. Treatment with Dalteparin is associated with a lower risk of bleeding compared to treatment with unfractionated heparin in patients with renal insufficiency[J]. J Gen Lntern Med, 2016,31(2):182-187.

Message Board

The pharmacotherapy practices of clinical pharmacist in Department of Critical Care Medicine

doi: 10.3969/j.issn.1006-0111.2017.04.021

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views